ASCO GU 2018 Bladder Cancer

Viewing 1-20 of 45 articles

ASCO GU 2018: Erdafitinib, (FGFR) a Pan-fibroblast Growth Factor Receptor Inhibitor, in Patients with Metastatic or Unresectable Urothelial Carcinoma and FGFR Alterations

ASCO GU 2018: Docetaxel with or without Ramucirumab After Immune Checkpoint Inhibition in Platinum-refractory Metastatic Urothelial Carcinoma (Muc): Prespecified Subgroup Analysis from the Phase 3 Range Trial

ASCO GU 2018: Size-focality-invasion in Upper Tract Urothelial Carcinoma - A Novel Imaging-Based Score To Predict Survival Outcomes

ASCO GU 2018: Effectiveness of Transurethral Resection Plus Systemic Chemotherapy as Definitive Treatment for Muscle-Invasive Bladder Cancer

ASCO GU 2018: Impact of Number of Cycles of Platinum-based First-line Chemotherapy for Advanced Urothelial Carcinoma

ASCO GU 2018: Clinical Outcomes of Patients with Histologic Variants of Urothelial Carcinoma Treated with Tetra-Modality Bladder-Sparing Protocol Incorporating Consolidative Partial Cystectomy

ASCO GU 2018: Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer

ASCO GU 2018: Utilization and Outcomes of Chemoprophylaxis for the Prevention of Venous Thromboembolism Following Radical Cystectomy: A Population-Based Study

ASCO GU 2018: Utility Of Lymph Node Dissection for Clinical Node Negative Upper Tract Urothelial Cell Carcinoma: A Multicenter Study

ASCO GU 2018: Defining the DNA Damage Repair Genomic Landscape of Urothelial Carcinoma of the Bladder

ASCO GU 2018: Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer

ASCO GU 2018: A Decision-Support Tool to Assist Muscle-Invasive Bladder Cancer Patients Choosing Between Radical Cystectomy and Chemoradiotherapy

ASCO GU 2018: Is Radical Radiotherapy Effective for Elderly Patients with Muscle Invasive Bladder Cancer?

ASCO GU 2018: Interim Results from PURE-01: A Phase 2, Open-Label Study of Neoadjuvant Pembrolizumab Before Radical Cystectomy for Muscle-Invasive Urothelial Bladder Carcinoma

ASCO GU 2018: A Randomized Phase III Double-Blind Clinical Trial (S1600) Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

ASCO GU 2018: Evaluation of a 29 Gene Classifier for Basal/Non Basal Prediction in Muscle-Invasive Bladder Cancer FFPE Samples

ASCO GU 2018: Role of Immunotherapy in Patients Undergoing Radiation Therapy for Bladder Cancer

ASCO GU 2018: Best of Journals: Urothelial Carcinoma - Medical Oncology

ASCO GU 2018: Nivolumab Plus Ipilimumab Versus Standard of Care with Previously Untreated Unresectable or Metastatic Urothelial Carcinoma

ASCO GU 2018: RNA-sequencing to Identify Three Different Molecular Grades and Immune Checkpoint Cascades with Distinct Clinical Behavior in NMIBC

1
2
3

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.